Blood Purification
Original Paper
Intradialytic Body Weight Changes and Dialyzer Pore Size as Main Contributing Factors to the Evolution of Beta-2-Microglobulin in DialysisVanholder R.C. · Ringoir S.M.Department of Nephrology, University Hospital, Gent, Belgium
|
|
Log in to MyKarger to check if you already have access to this content.
KAB
Buy a Karger Article Bundle (KAB) and profit from a discount!
If you would like to redeem your KAB credit, please log in.
Save over 20% compared to the individual article price.
Article / Publication Details
Accepted: October 05, 1989
Published online: October 29, 2008
Issue release date: 1990
Number of Print Pages: 13
Number of Figures: 0
Number of Tables: 0
ISSN: 0253-5068 (Print)
eISSN: 1421-9735 (Online)
For additional information: https://www.karger.com/BPU
Abstract
Cuprophane hemodialysis is associated with an early fall of leukocyte counts and an intradialytic rise in serum β2-microglobulin (β2M), in contrast to dialysis with more compatible dialyzers. It has been suggested that these two phenomena may be related. This study sets out to verify this hypothesis by comparing the evolution of leukocyte counts with that of β2M: (1) during dialysis with 5 dialyzer types with different pore size and/or leukocyte biocompatibility; (2) during first use and reuse of 3 dialyzer types, and (3) during sequential ultrafiltration and dialysis with cuprophane. In first-use dialyses, no relation could be found between changes in leukocyte counts and the evolution of β2M levels. Reuse of cuprophane and saponified cellulose ester resulted in a marked attenuation of the intradialytic fall in leukocyte counts after 15 min (change in white blood cell count: -72 and -17% for first-use and third-reuse cuprophane, -72 and -23% for saponified cellulose, respectively), but had no influence on the increase in β2M. Correlation studies of these data revealed that the intradialytic evolution of β2M was related to membrane pore size and, for membranes with a small pore size, to the intradialytic fluid losses: first-use cuprophane (p < 0.05), saponified cellulose ester (p < 0.001) and hemophane (p < 0.01), and pooled first-use and reuse cuprophane and saponified cellulose ester (p < 0.001). Cuprophane dialysis without ultrafiltration (dialysate Na+: 138 and 132 mEq/1) caused a fall in leukocytes, but induced no rise in β2M. Ultrafiltration with cuprophane either preceding or following dialysis consistently caused a rise in serum β2M, although a fall in leukocyte counts only occurred in the first case. Our data point away from a relationship between membrane biocompatibility, expressed as changes in leukocyte counts, and β2M concentration during hemodialysis. The major contributing factors appear to be dialytic fluid losses and membrane pore size.
© 1990 S. Karger AG, Basel
Related Articles:
Article / Publication Details
Accepted: October 05, 1989
Published online: October 29, 2008
Issue release date: 1990
Number of Print Pages: 13
Number of Figures: 0
Number of Tables: 0
ISSN: 0253-5068 (Print)
eISSN: 1421-9735 (Online)
For additional information: https://www.karger.com/BPU
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
Get Permission
PubMed ID
